AU2011262494B2 - Fusion protein having factor VII activity - Google Patents

Fusion protein having factor VII activity Download PDF

Info

Publication number
AU2011262494B2
AU2011262494B2 AU2011262494A AU2011262494A AU2011262494B2 AU 2011262494 B2 AU2011262494 B2 AU 2011262494B2 AU 2011262494 A AU2011262494 A AU 2011262494A AU 2011262494 A AU2011262494 A AU 2011262494A AU 2011262494 B2 AU2011262494 B2 AU 2011262494B2
Authority
AU
Australia
Prior art keywords
fvii
fusion protein
linker
transferrin
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011262494A
Other languages
English (en)
Other versions
AU2011262494A1 (en
AU2011262494A2 (en
Inventor
Hun-Taek Kim
Min-Sun Kim
Bong-Yong Lee
Ho-Soon Lee
Ji-Hye Lee
Yun Jung Lim
Mahn-Hoon Park
Seo Yeon Son
In-Young Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tiumbio Co Ltd
Original Assignee
Tiumbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tiumbio Co Ltd filed Critical Tiumbio Co Ltd
Publication of AU2011262494A1 publication Critical patent/AU2011262494A1/en
Publication of AU2011262494A2 publication Critical patent/AU2011262494A2/en
Application granted granted Critical
Publication of AU2011262494B2 publication Critical patent/AU2011262494B2/en
Assigned to TIUMBIO CO., LTD. reassignment TIUMBIO CO., LTD. Request for Assignment Assignors: SK CHEMICALS CO., LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2011262494A 2010-06-04 2011-06-07 Fusion protein having factor VII activity Active AU2011262494B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2010-0052719 2010-06-04
KR20100052719 2010-06-04
PCT/KR2011/004131 WO2011152694A2 (en) 2010-06-04 2011-06-07 Fusion protein having factor vii activity

Publications (3)

Publication Number Publication Date
AU2011262494A1 AU2011262494A1 (en) 2013-01-24
AU2011262494A2 AU2011262494A2 (en) 2013-08-01
AU2011262494B2 true AU2011262494B2 (en) 2016-01-21

Family

ID=45067214

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011262494A Active AU2011262494B2 (en) 2010-06-04 2011-06-07 Fusion protein having factor VII activity

Country Status (13)

Country Link
US (2) US9644197B2 (enExample)
EP (1) EP2576625B1 (enExample)
JP (2) JP6143297B2 (enExample)
KR (1) KR101331101B1 (enExample)
CN (2) CN107188970A (enExample)
AU (1) AU2011262494B2 (enExample)
BR (1) BR112012030941A2 (enExample)
CA (1) CA2801223C (enExample)
ES (1) ES2676874T3 (enExample)
MX (1) MX348567B (enExample)
RU (1) RU2585231C2 (enExample)
WO (1) WO2011152694A2 (enExample)
ZA (1) ZA201300066B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9644197B2 (en) 2010-06-04 2017-05-09 Sk Chemicals Co., Ltd. Fusion protein having factor VII activity
MX349054B (es) * 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
WO2014129876A1 (ko) 2013-02-25 2014-08-28 에스케이케미칼주식회사 인자 vii을 포함하는 융합 단백질의 분리 및 정제 방법
KR102058864B1 (ko) * 2013-12-16 2019-12-24 주식회사 티움바이오 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
UA129696C2 (uk) 2017-08-18 2025-07-09 Ньютроліс Інк. СКОНСТРУЙОВАНІ ФЕРМЕНТИ ДНКази ТА ЇХНЄ ЗАСТОСУВАННЯ В ТЕРАПІЇ
CN112996911A (zh) 2018-10-08 2021-06-18 纽特雷斯股份有限公司 用于制造和疗法的脱氧核糖核酸酶的工程改造
CN110218259B (zh) * 2019-06-24 2022-09-16 王跃驹 植物生产胰高血糖素样肽-1短肽与转铁蛋白的融合蛋白制造口服降糖胶囊的应用
CN110229237A (zh) * 2019-06-24 2019-09-13 王跃驹 植物生产口服epo与转铁蛋白融合蛋白胶囊的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020746A1 (en) * 2001-08-30 2003-03-13 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
CN101177456A (zh) * 2001-08-30 2008-05-14 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
CN100412090C (zh) * 2002-05-01 2008-08-20 舍林股份公司 作为抗凝剂的新的靶向组织因子的血栓调节蛋白融合蛋白
US20070072271A1 (en) * 2004-01-07 2007-03-29 Novo Nordisk Healthcare A/G Method for the production of recombinant proteins
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
TWI428448B (zh) * 2006-03-24 2014-03-01 Syntonix Pharmaceuticals Inc 作為第九因子（ｆａｃｔｏｒ ｉｘ）原肽處理酶之ｐｃ５
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2009086132A2 (en) 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
CN105727261A (zh) 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
CN102647945B (zh) * 2009-12-08 2015-07-29 皇家飞利浦电子股份有限公司 用于校正示踪剂摄取测量结果的方法和校正系统
US9644197B2 (en) 2010-06-04 2017-05-09 Sk Chemicals Co., Ltd. Fusion protein having factor VII activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020746A1 (en) * 2001-08-30 2003-03-13 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains

Also Published As

Publication number Publication date
EP2576625A4 (en) 2013-11-06
JP6422918B2 (ja) 2018-11-14
ZA201300066B (en) 2014-03-26
MX2012013807A (es) 2012-12-17
JP2013529914A (ja) 2013-07-25
AU2011262494A1 (en) 2013-01-24
EP2576625A2 (en) 2013-04-10
ES2676874T3 (es) 2018-07-25
JP2017000144A (ja) 2017-01-05
WO2011152694A2 (en) 2011-12-08
US10696960B2 (en) 2020-06-30
US9644197B2 (en) 2017-05-09
WO2011152694A3 (en) 2012-04-19
RU2585231C2 (ru) 2016-05-27
WO2011152694A8 (en) 2013-01-17
CA2801223A1 (en) 2011-12-08
RU2012157301A (ru) 2014-07-20
EP2576625B1 (en) 2018-04-25
KR101331101B1 (ko) 2013-11-19
BR112012030941A2 (pt) 2017-06-06
KR20110133454A (ko) 2011-12-12
US20130236945A1 (en) 2013-09-12
CN103068854A (zh) 2013-04-24
CN107188970A (zh) 2017-09-22
MX348567B (es) 2017-06-20
US20160194622A1 (en) 2016-07-07
JP6143297B2 (ja) 2017-06-07
CA2801223C (en) 2019-12-03
AU2011262494A2 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
US10696960B2 (en) Fusion protein having factor VII activity
SG186875A1 (en) Chimeric clotting factors
JP2008509688A (ja) 改変ビタミンｋ依存性ポリペプチド
RS50743B (sr) Proizvodnja rekombinantnih faktora koagulacije krvi u humanim ćelijama
CA2981467C (en) Fusion protein with factor ix activity
AU2020242945B2 (en) Factor IX variants and uses thereof in therapy
US20220259287A1 (en) Single chain factor viii molecule
US20160060612A1 (en) Method of Isolating and Purifying Fusion Protein Comprising Factor VII
US20250177571A1 (en) Sequence of activated protein c

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 JAN 2013

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TIUMBIO CO., LTD.

Free format text: FORMER OWNER(S): SK CHEMICALS CO., LTD.